The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 9910 malaria professionals are enjoying the free benefits of MalariaWorld today

The 2006 pioneering clinical trials Artemisia annua vs ACT in Cameroon

April 17, 2018 - 08:02 -- Pierre Lutgen

                       Etude comparative de l’efficacité in vivo de l’artesunate avec l’amodiaquine et la tisane Artemisia annacultivée à Bangangté à l’Ouest du Cameroun

Chougouo Kengne R.D*., Kouamouo J*., Moyou Somo R**., Penge On’Okoko A***. *Université des Montagnes, Bangangté, Cameroun ; ** IMPM /CRM et FMSB Cameroun; *** Université de Kinshasa RDC. 

Abstract (excerpt):

This work was carried out period of June in October 2006 at the hospital of district of Bangangté It aimed to compare the effectiveness of Artesunate alone, in partnership with Amodiaquine on P. falciparum and the same time study of therapeutic effectiveness of Artemisia annua like plants antimalaria in the department of the NDE. The Artesunate took in 5 days and Artesunate/Amodiaquine association took in 3 days gave 81,25% and 85,70% respectively. The herb tea of Artemisia annua taken in 5 days or 7 days gives the following therapeutic response respectively: 71, 3% and 100%. It is noted that the therapeutic response of herb teas is improved by prolonging the time. Adverse events associated with Artesunate is the sensation of hyperthermia while those related to the association Artesunate / Amodiaquine is mainly myalgia, anorexia,abdominal pain

 

                                                                    THE FULL TEXT IS AVAILABLE IN FRENCH IN THE ATTACHED PDF

                                                                      Annales de Pharmacie- Université de Kinshasa. 2012, 4-1, 127-148

AttachmentSize
PDF icon rosineannaleskinshasa.pdf2.11 MB

Comments

Submitted by Irene Teis on

MIM was established in 1997 with a mission to strengthen the capacity of malaria-endemic countries in Africa to carry out research that is required to develop and improve tools for malaria control.
It is thus surprising that none of the recent clinical trials carried out in several African countries by African doctors and universities, with Artemisia plants, which not only give cure rates close to 100%, eliminate gametocytes and transmission but also show stronger prophylactic properties than current antimalarial vaccines, that none of these be presented and discussed at the Dakar conference.

Submitted by Philip JAJOSKY on

Germany had "the Berlin patient" -- Africa should introduce "the T-REX patients."

In Burkina Faso, life-threatening parasite-induced appendicitis is successfully treated via appendectomy. T-REX is much simpler than an appendectomy and can -- and should -- be immediately evaluated to prevent death via cerebral malaria.

free-access link to Elsevier TRASCI article titled

To prevent or ameliorate severe Plasmodium falciparum malaria, why not evaluate the impact of exchange transfusions of sickle cell trait red blood cells?

https://authors.elsevier.com/c/1Wsl85Exiwy4mx

Philip Jajosky, MD (retired CDC, USPHS)
Ryan Jajosky, MD (Emory University, USA)
Audrey Jajosky, MD, PhD (Case Western Reserve University, USA)

Also, JNHRC (Journal of Nepal Health Research Council) has another free-access T-REX article if you're interested. JNHRC is a very nice, free, open-access journal.

Philip Jajosky, MD, MPH